A new kind of antibody targets a feature shared by proteins thought to cause the most damage in Alzheimer’s disease, Parkinson’s disease, and related conditions, creating potential for a unified treatment approach.
This is the finding of a study led by researchers from NYU School of Medicine and published online August 29 in Scientific Reports.
The new study is based on decades of work arguing that the contribution to disease of key proteins—amyloid beta and tau in Alzheimer’s disease, alpha-synuclein in Parkinson’s disease, and prion proteins in conditions like mad cow disease—is driven by certain, toxic forms dominated by a common structure: bundles of “beta sheets” in clumped proteins.
In tissues from autopsied patients with these diseases and in live mice, experiments demonstrated how the study antibodies target and remove only these toxic forms, say the authors, and without triggering the immune toxicity that has frustrated treatment development efforts to date.
“In an atmosphere where countless treatments have failed in clinical trials over the last 15 years, the fact that our approach continues to be effective in rigorous tests should be of interest to our peers and the industry, even if it runs contrary to conventional thinking,” says corresponding author Fernando Goni, PhD, research associate professor in the Department of Neurology at NYU Langone Health.
“While we still have a number of milestones to reach before this work is ready for clinical testing, our results suggest that these antibodies may halt key pathological mechanisms across several neurological diseases and regardless of disease stage,” says corresponding author Thomas Wisniewski, MD, director of NYU Langone’s Center for Cognitive Neurology, Silberstein Alzheimer’s Institute, and Alzheimer’s Disease Center.
New Approach to Antibody Design
The study focuses on proteins that form important structures in the brain. The instant they form as chains of amino acids, proteins fold into complex shapes needed to do their jobs. Unfortunately, proteins can also “misfold” for countless reasons, such as genetic abnormalities, toxins, age-associated cell processes, and inflammation that eventually cause the diseases addressed by the current study. Cells and tissues die as misshapen proteins stop working and build up, but the field has struggled to pinpoint which of these shifting forms to target as the key drivers of disease.
Many research efforts, including the current study, seek to design antibodies shaped to attach to and remove the right targets. Past and ongoing attempts have targeted the initial, short chains of amino acids that serve as basic, repeating structural units, or monomers, of each misfolded protein. Still others targeted end-stage fibrils, each made of thousands of monomers, which accumulate in plaques and tangles that tissues cannot eliminate. Neither approach has yielded an effective therapy.
In that light, Dr. Goni, Dr. Wisniewski, and colleagues designed their antibodies to target instead the “oligomers” formed as several misfolded monomers associate and acquire the “beta-sheet” shape, but before they are large enough to fibrilize. These intermediate forms may be uniquely toxic, say many in the field, because, unlike fibrils, they can dissolve, move in and out of cells, and from one cell to another. This mobility may explain the “prion-like” progression seen in misfolding diseases where abnormal proteins cause normal ones to misfold in a domino effect that damages nerve cells and their connections in the brain.
Importantly, growing toxic oligomers of amyloid beta, tau, alpha synuclein, and prion protein become increasingly dominated by the twisted strands of amino acids called beta sheets, which have spatial arrangements that let the strands stack up.
To design new kinds of antibodies, the research team zeroed in on a small 13-amino acid peptide, derived from the extremely rare genetic disease called British amyloidosis, but not present in the rest of the human population. They converted it into a larger, stable oligomer with more than 90 percent “beta-sheet” structure—the p13Bri immunogen—that could be “seen” by the mammalian immune system, and that could trigger a specific antibody response to solve problems encountered with standard approaches. By immunizing mice with p13Bri at high doses, they forced the production of extremely rare antibodies against beta sheets in toxic oligomers.
The researchers say that their rare antibodies, activated by a protein fragment seen only in a rare disease, have almost zero chance of triggering unwanted immune responses to normal proteins with similar sequences (autotoxicity), the downfall of many previous attempts. Finally, the team screened their lead antibodies against tissues taken from the brains of human patients with Alzheimer’s disease, Parkinson’s disease, and prion diseases. Only the six monoclonal antibodies that reacted to toxic oligomers from at least two misfolded proteins from two diseases were selected for further study.
“This publication details the first system for making antibodies that truly target only toxic oligomers of misfolded proteins dominated by beta sheets across several diseases, and without regard to the amino acid makeup of each misfolded protein’s monomer,” says Dr. Goni.
The Latest on: Neurological diseases
- Family tries to cure toddler with rare genetic diseaseon October 18, 2019 at 9:44 am
A Denver family is trying to raise $3 million in order to cure their son with a rare genetic disease. Doctors told Amber Freed that her 2-year-old son is one of 34 people in the world to have this ...
- Panel grapples with '65 mph disease' without answerson October 18, 2019 at 4:19 am
Lawmakers and witnesses called for greater funding and collaboration yesterday to fight a degenerative neurological disease that is killing deer, elk and moose in 26 states. By signing up, you agree ...
- Editas Inks Deal for Gene Editing Neurological Disease Drugson October 16, 2019 at 2:32 pm
Editas Medicine, Inc. EDIT announced that it has entered into a strategic research collaboration with privately held gene therapy company Asklepios BioPharmaceutical (AskBio) to jointly explore in ...
- Study focuses on repair and reversal of damage caused by Huntington's diseaseon October 16, 2019 at 11:06 am
People with Huntington's experience depression, irritability and other neurological and behavioral problems. They may also have difficulty processing information and controlling their body's movements ...
- Intracranial Stents Market Will Benefit from High Prevalence of Neurological Disorderson October 15, 2019 at 1:12 am
What are the key companies operating in the market? Which company accounted for the highest market share? The high prevalence of neurological disorders has provoked several innovations in treatment ...
- Sia details struggle with Ehlers-Danlos, neurological diseaseon October 7, 2019 at 8:01 am
Oct. 7 (UPI) --Sia is sharing more details about her struggle with Ehlers-Danlos syndrome and a neurological disease. The 43-year-old Australian singer and songwriter discussed her health Sunday on ...
- Spatial Gene Expression Profiling of Neurological Disorderson October 7, 2019 at 5:01 am
In this interview, Cedric Uytingco discusses the key benefits of being able to visualize gene expression patterns in neurological samples. Traditionally ... alone can obscure information that is ...
- Research Roundup: Echolocation, neurological disease and breast cancer clinical trialson October 6, 2019 at 10:58 pm
Collaborative study finds the cause of a rare neurological disease A collaborative study between scientists from the Stanford School of Medicine, University of California, San Francisco and the ...
- Sia reveals she has a chronic neurological disease and genetic disorderon October 6, 2019 at 6:58 pm
Sia has just joined the ranks of stars speaking out about their health issues by announcing she suffers from chronic pain, a neurological disease and the group of genetic syndromes known as ...
- Sia reveals she suffers from rare neurological diseaseon October 5, 2019 at 10:14 am
Singer Sia opened up to fans this week about the state of her health, revealing that she suffers from “chronic pain” due to a neurological disease. “Hey, I’m suffering with chronic pain ...
via Google News and Bing News